KNSA Straddle Strategy
KNSA (Kiniksa Pharmaceuticals International, plc), in the Healthcare sector, (Medical - Pharmaceuticals industry), listed on NASDAQ.
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
KNSA (Kiniksa Pharmaceuticals International, plc) trades in the Healthcare sector, specifically Medical - Pharmaceuticals, with a market capitalization of approximately $4.45B, a trailing P/E of 62.00, a beta of 0.12 versus the broader market, a 52-week range of 26.27-61.123, average daily share volume of 770K, a public-listing history dating back to 2018, approximately 366 full-time employees. These structural characteristics shape how KNSA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.12 indicates KNSA has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 62.00 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.
What is a straddle on KNSA?
A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.
Current KNSA snapshot
As of June 30, 2026, spot at $63.84, ATM IV 44.10%, IV rank 22.06%, expected move 12.64%. The straddle on KNSA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this straddle structure on KNSA specifically: KNSA IV at 44.10% is on the cheap side of its 1-year range, which favors premium-buying structures like a KNSA straddle, with a market-implied 1-standard-deviation move of approximately 12.64% (roughly $8.07 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated KNSA expiries trade a higher absolute premium for lower per-day decay. Position sizing on KNSA should anchor to the underlying notional of $63.84 per share and to the trader's directional view on KNSA stock.
KNSA straddle setup
The KNSA straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With KNSA near $63.84, the first option leg uses a $63.84 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed KNSA chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 KNSA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $63.84 | N/A |
| Buy 1 | Put | $63.84 | N/A |
KNSA straddle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.
KNSA straddle payoff curve
Modeled P&L at expiration across a range of underlying prices for the straddle on KNSA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use straddle on KNSA
Straddles on KNSA are pure-volatility plays that profit from large moves in either direction; traders typically buy KNSA straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
KNSA thesis for this straddle
The market-implied 1-standard-deviation range for KNSA extends from approximately $55.77 on the downside to $71.91 on the upside. A KNSA long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current KNSA IV rank near 22.06% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on KNSA at 44.10%. As a Healthcare name, KNSA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to KNSA-specific events.
KNSA straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. KNSA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move KNSA alongside the broader basket even when KNSA-specific fundamentals are unchanged. Always rebuild the position from current KNSA chain quotes before placing a trade.
Frequently asked questions
- What is a straddle on KNSA?
- A straddle on KNSA is the straddle strategy applied to KNSA (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With KNSA stock trading near $63.84, the strikes shown on this page are snapped to the nearest listed KNSA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are KNSA straddle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the KNSA straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 44.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a KNSA straddle?
- The breakeven for the KNSA straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current KNSA market-implied 1-standard-deviation expected move is approximately 12.64%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a straddle on KNSA?
- Straddles on KNSA are pure-volatility plays that profit from large moves in either direction; traders typically buy KNSA straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
- How does current KNSA implied volatility affect this straddle?
- KNSA ATM IV is at 44.10% with IV rank near 22.06%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.